Wilson Nathaniel R, Chauhan Siddharth, Aisenberg Gabriel
Internal Medicine, University of Texas Health Science Center at Houston, Houston, USA.
Cureus. 2020 Aug 19;12(8):e9867. doi: 10.7759/cureus.9867.
Hydralazine-induced lupus syndrome (HILS) is a rare clinical entity with variable manifestations. Pericardial involvement is an uncommon but serious manifestation of the condition. In this report, we present a case of large symptomatic pericardial effusion secondary to HILS. We highlight the important considerations in the evaluation and management of this rare syndrome. HILS should be considered in the differential diagnosis for cardiac tamponade of otherwise unclear etiology in patients taking 100 mg daily or more of hydralazine for longer than three months. A temporal association between the offending drug and presenting symptoms, resolution of symptoms upon discontinuation, and a positive anti-histone antibody test can all support the diagnosis of this syndrome.
肼屈嗪诱发的狼疮综合征（HILS）是一种临床表现多样的罕见临床病症。心包受累是该病症一种不常见但严重的表现。在本报告中，我们呈现了一例继发于HILS的大量有症状心包积液病例。我们强调了对这一罕见综合征进行评估和管理时的重要注意事项。对于服用每日100毫克或更多肼屈嗪超过三个月、病因不明的心源性心包填塞患者，鉴别诊断时应考虑HILS。致病药物与出现症状之间的时间关联、停药后症状缓解以及抗组蛋白抗体检测呈阳性均有助于支持该综合征的诊断。
